Top

European Journal of Drug Metabolism and Pharmacokinetics

Published in:

01-03-2021 | SARS-CoV-2 | Review Article

Potential Effects of COVID-19 on Cytochrome P450-Mediated Drug Metabolism and Disposition in Infected Patients

Authors: Subrata Deb, Scott Arrighi

Published in: European Journal of Drug Metabolism and Pharmacokinetics | Issue 2/2021

Abstract

Coronavirus Disease 2019 (COVID-19) has been a global health crisis since it was first identified in December 2019. In addition to fever, cough, headache, and shortness of breath, an intense increase in immune response-based inflammation has been the hallmark of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) virus infection. This narrative review summarizes and critiques pathophysiology of COVID-19 and its plausible effects on drug metabolism and disposition. The release of inflammatory cytokines (e.g., interleukins, tumor necrosis factor α), also known as ‘cytokine storm’, leads to altered molecular pathophysiology and eventually organ damage in the lung, heart, and liver. The laboratory values for various liver function tests (e.g., alanine aminotransferase, aspartate aminotransferase, total bilirubin, albumin) have indicated potential hepatocellular injury in COVID-19 patients. Since the liver is the powerhouse of protein synthesis and the primary site of cytochrome P450 (CYP)-mediated drug metabolism, even a minor change in the liver function status has the potential to affect the hepatic clearance of xenobiotics. It has now been well established that extreme increases in cytokine levels are common in COVID-19 patients, and previous studies with patients infected with non-SARS-CoV-2 virus have shown that CYP enzymes can be suppressed by an infection-related cytokine increase and inflammation. Alongside the investigational COVID-19 drugs, the patients may also be on therapeutics for comorbidities; especially epidemiological studies have indicated that individuals with hypertension, hyperglycemia, and obesity are more vulnerable to COVID-19 than the average population. This complicates the drug-disease interaction profile of the patients as both the investigational drugs (e.g., remdesivir, dexamethasone) and the agents for comorbidities can be affected by compromised CYP-mediated hepatic metabolism. Overall, it is imperative that healthcare professionals pay attention to the COVID-19 and CYP-driven drug metabolism interactions with the goal to adjust the dose or discontinue the affected drugs as appropriate.

World Health Organization (WHO). WHO Coronavirus Disease (COVID-19) Dashboard. 2020. https://covid19.who.int/. Accessed 14 Oct 2020.

World Health Organization (WHO). Coronavirus disease (COVID-19) pandemic. 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed 14 Oct 2020.

Rodriguez-Morales AJ, Cardona-Ospina JA, Gutierrez-Ocampo E, Villamizar-Pena R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis. 2020;34:101623. https://doi.org/10.1016/j.tmaid.2020.101623.CrossRefPubMedPubMedCentral

Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–5. https://doi.org/10.1016/j.ijid.2020.03.017.CrossRefPubMedPubMedCentral

Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, et al. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum Vaccin Immunother. 2020;16(6):1232–8. https://doi.org/10.1080/21645515.2020.1735227.CrossRefPubMedPubMedCentral

Kang S, Peng W, Zhu Y, Lu S, Zhou M, Lin W, et al. Recent progress in understanding 2019 novel coronavirus (SARS-CoV-2) associated with human respiratory disease: detection, mechanisms and treatment. Int J Antimicrob Agents. 2020;55(5):105950. https://doi.org/10.1016/j.ijantimicag.2020.105950.CrossRefPubMedPubMedCentral

Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis. Arch Acad Emerg Med. 2020;8(1):e35.PubMedPubMedCentral

Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients. J Infect. 2020;80(6):e14–8. https://doi.org/10.1016/j.jinf.2020.03.005.CrossRefPubMedPubMedCentral

Gao Y, Li T, Han M, Li X, Wu D, Xu Y, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. 2020;92(7):791–6. https://doi.org/10.1002/jmv.25770.CrossRefPubMed

10.

Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811–8. https://doi.org/10.1001/jamacardio.2020.1017.CrossRefPubMed

11.

Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631–7. https://doi.org/10.1002/path.1570.CrossRefPubMedPubMedCentral

12.

U.S. Food and Drug Administration. FDA Drug Shortages. 2020. https://www.accessdata.fda.gov/scripts/drugshortages/. Accessed 14 Oct 2020.

13.

Higgs A, McGrath BA, Goddard C, Rangasami J, Suntharalingam G, Gale R, et al. Guidelines for the management of tracheal intubation in critically ill adults. Br J Anaesth. 2018;120(2):323–52. https://doi.org/10.1016/j.bja.2017.10.021.CrossRefPubMed

14.

Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients. Am J Roentgenol. 2020;215(1):87–93. https://doi.org/10.2214/AJR.20.23034.CrossRef

15.

Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–4. https://doi.org/10.1016/S0140-6736(20)30628-0.CrossRefPubMedPubMedCentral

16.

Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34(2):327–31. https://doi.org/10.23812/CONTI-E.CrossRefPubMed

17.

Li J, Fan JG. Characteristics and mechanism of liver injury in 2019 coronavirus disease. J Clin Transl Hepatol. 2020;8(1):13–7. https://doi.org/10.14218/JCTH.2020.00019.CrossRefPubMedPubMedCentral

18.

Wang F, Yang Y, Dong K, Yan Y, Zhang S, Ren H, et al. Clinical characteristics of 28 patients with diabetes and Covid-19 in Wuhan, China. Endocr Pract. 2020;26(6):668–74. https://doi.org/10.4158/EP-2020-0108.CrossRefPubMedPubMedCentral

19.

Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091. https://doi.org/10.1136/bmj.m1091.CrossRefPubMedPubMedCentral

20.

Chen Q, Xu L, Dai Y, Ling Y, Mao J, Qian J, et al. Cardiovascular manifestations in severe and critical patients with COVID-19. Clin Cardiol. 2020;43(7):796–802. https://doi.org/10.1002/clc.23384.CrossRefPubMedPubMedCentral

21.

Zhu Z, Cai T, Fan L, Lou K, Hua X, Huang Z, et al. Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019. Int J Infect Dis. 2020;95:332–9. https://doi.org/10.1016/j.ijid.2020.04.041.CrossRefPubMedPubMedCentral

22.

Huang H, Song B, Xu Z, Jiao Y, Huang L, Zhao P, et al. Predictors of coronavirus disease 2019 severity: a retrospective study of 64 cases. Jpn J Infect Dis. 2019. https://doi.org/10.7883/yoken.JJID.2020.298.CrossRef

23.

Petrey AC, Qeadan F, Middleton EA, Pinchuk IV, Campbell RA, Beswick EJ. Cytokine release syndrome in COVID-19: innate immune, vascular, and platelet pathogenic factors differ in severity of disease and sex. J Leukoc Biol. 2020. https://doi.org/10.1002/JLB.3COVA0820-410RRR.CrossRefPubMed

24.

Zou L, Dai L, Zhang Y, Fu W, Gao Y, Zhang Z, et al. Clinical characteristics and risk factors for disease severity and death in patients with coronavirus disease 2019 in Wuhan, China. Front Med (Lausanne). 2020;7:532. https://doi.org/10.3389/fmed.2020.00532.CrossRef

25.

Russell B, Moss C, George G, Santaolalla A, Cope A, Papa S, et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancermedicalscience. 2020;14:1022. https://doi.org/10.3332/ecancer.2020.1022.CrossRefPubMedPubMedCentral

26.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5.CrossRefPubMedPubMedCentral

27.

Musa S. Hepatic and gastrointestinal involvement in coronavirus disease 2019 (COVID-19): what do we know till now? Arab J Gastroenterol. 2020;21(1):3–8. https://doi.org/10.1016/j.ajg.2020.03.002.CrossRefPubMedPubMedCentral

28.

Bangash MN, Patel J, Parekh D. COVID-19 and the liver: little cause for concern. Lancet Gastroenterol Hepatol. 2020;5(6):529–30. https://doi.org/10.1016/S2468-1253(20)30084-4.CrossRefPubMedPubMedCentral

29.

Liu F, Xu A, Zhang Y, Xuan W, Yan T, Pan K, et al. Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression. Int J Infect Dis. 2020;95:183–91. https://doi.org/10.1016/j.ijid.2020.03.013.CrossRefPubMedPubMedCentral

30.

Deb S, Puthanveetil P, Sakharkar P. A population-based cross-sectional study of the association between liver enzymes and lipid levels. Int J Hepatol. 2018;2018:1286170. https://doi.org/10.1155/2018/1286170.CrossRefPubMedPubMedCentral

31.

Sakharkar P, Deb S, Mashayekhi N. Association between polymorphisms in cytokine gene and viral infections in renal and liver transplant recipients: a systematic review. J Pharm Pharm Sci. 2020;23(1):109–31. https://doi.org/10.18433/jpps30961.CrossRefPubMed

32.

Newsome PN, Cramb R, Davison SM, Dillon JF, Foulerton M, Godfrey EM, et al. Guidelines on the management of abnormal liver blood tests. Gut. 2018;67(1):6–19. https://doi.org/10.1136/gutjnl-2017-314924.CrossRefPubMed

33.

Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol. 2017;112(1):18–35. https://doi.org/10.1038/ajg.2016.517.CrossRefPubMed

34.

Feng G, Zheng KI, Yan QQ, Rios RS, Targher G, Byrne CD, et al. COVID-19 and liver dysfunction: current insights and emergent therapeutic strategies. J Clin Transl Hepatol. 2020;8(1):18–24. https://doi.org/10.14218/JCTH.2020.00018.CrossRefPubMedPubMedCentral

35.

Hong KS, Lee KH, Chung JH, Shin KC, Choi EY, Jin HJ, et al. Clinical features and outcomes of 98 patients hospitalized with SARS-CoV-2 infection in Daegu, South Korea: a brief descriptive study. Yonsei Med J. 2020;61(5):431–7. https://doi.org/10.3349/ymj.2020.61.5.431.CrossRefPubMedPubMedCentral

36.

Sverrisdottir E, Lund TM, Olesen AE, Drewes AM, Christrup LL, Kreilgaard M. A review of morphine and morphine-6-glucuronide’s pharmacokinetic-pharmacodynamic relationships in experimental and clinical pain. Eur J Pharm Sci. 2015;74:45–62. https://doi.org/10.1016/j.ejps.2015.03.020.CrossRefPubMed

37.

Renton KW. Regulation of drug metabolism and disposition during inflammation and infection. Expert Opin Drug Metab Toxicol. 2005;1(4):629–40. https://doi.org/10.1517/17425255.1.4.629.CrossRefPubMed

38.

Callahan SM, Wonganan P, Croyle MA. Molecular and macromolecular alterations of recombinant adenoviral vectors do not resolve changes in hepatic drug metabolism during infection. Virol J. 2008;5:111. https://doi.org/10.1186/1743-422X-5-111.CrossRefPubMedPubMedCentral

39.

Kim S, Ostor AJ, Nisar MK. Interleukin-6 and cytochrome-P450, reason for concern? Rheumatol Int. 2012;32(9):2601–4. https://doi.org/10.1007/s00296-012-2423-3.CrossRefPubMed

40.

Li AP, Yang Q, Vermet H, Raoust N, Klieber S, Fabre G. Evaluation of human hepatocytes under prolonged culture in a novel medium for the maintenance of hepatic differentiation: results with the model pro-inflammatory cytokine interleukin 6. Drug Metab Lett. 2014;8(1):12–8. https://doi.org/10.2174/187231280801140929155351.CrossRefPubMed

41.

Croyle MA. Long-term virus-induced alterations of CYP3A-mediated drug metabolism: a look at the virology, immunology and molecular biology of a multi-faceted problem. Expert Opin Drug Metab Toxicol. 2009;5(10):1189–211. https://doi.org/10.1517/17425250903136748.CrossRefPubMed

42.

Aitken AE, Morgan ET. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos. 2007;35(9):1687–93. https://doi.org/10.1124/dmd.107.015511.CrossRefPubMed

43.

Pascussi JM, Dvorak Z, Gerbal-Chaloin S, Assenat E, Maurel P, Vilarem MJ. Pathophysiological factors affecting CAR gene expression. Drug Metab Rev. 2003;35(4):255–68. https://doi.org/10.1081/dmr-120026394.CrossRefPubMed

44.

Rasmussen MK, Bertholdt L, Gudiksen A, Pilegaard H, Knudsen JG. Impact of fasting followed by short-term exposure to interleukin-6 on cytochrome P450 mRNA in mice. Toxicol Lett. 2018;282:93–9. https://doi.org/10.1016/j.toxlet.2017.10.011.CrossRefPubMed

45.

Moreau A, Le Vee M, Jouan E, Denizot C, Parmentier Y, Fardel O. Effect of gevokizumab on interleukin-1beta-mediated cytochrome P450 3A4 and drug transporter repression in cultured human hepatocytes. Eur J Drug Metab Pharmacokinet. 2017;42(5):871–8. https://doi.org/10.1007/s13318-017-0406-1.CrossRefPubMed

46.

Cheng PY, Morgan ET. Hepatic cytochrome P450 regulation in disease states. Curr Drug Metab. 2001;2(2):165–83. https://doi.org/10.2174/1389200013338676.CrossRefPubMed

47.

Renton KW. Cytochrome P450 regulation and drug biotransformation during inflammation and infection. Curr Drug Metab. 2004;5(3):235–43. https://doi.org/10.2174/1389200043335559.CrossRefPubMed

48.

Chen YL, Le Vraux V, Leneveu A, Dreyfus F, Stheneur A, Florentin I, et al. Acute-phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics. Clin Pharmacol Ther. 1994;55(6):649–60. https://doi.org/10.1038/clpt.1994.82.CrossRefPubMed

49.

Machavaram KK, Almond LM, Rostami-Hodjegan A, Gardner I, Jamei M, Tay S, et al. A physiologically based pharmacokinetic modeling approach to predict disease-drug interactions: suppression of CYP3A by IL-6. Clin Pharmacol Ther. 2013;94(2):260–8. https://doi.org/10.1038/clpt.2013.79.CrossRefPubMed

50.

Varkhede N, Patel N, Chang W, Ruterbories K, Forrest ML. A semi-physiologically based pharmacokinetic model describing the altered metabolism of midazolam due to inflammation in mice. Pharm Res. 2018;35(8):162. https://doi.org/10.1007/s11095-018-2447-9.CrossRefPubMedPubMedCentral

51.

Seifert SM, Castillo-Mancilla JR, Erlandson KM, Anderson PL. Inflammation and pharmacokinetics: potential implications for HIV-infection. Expert Opin Drug Metab Toxicol. 2017;13(6):641–50. https://doi.org/10.1080/17425255.2017.1311323.CrossRefPubMed

52.

Sorgel F, Malin JJ, Hagmann H, Kinzig M, Bilal M, Eichenauer DA, et al. Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent haemodialysis. J Antimicrob Chemother. 2020. https://doi.org/10.1093/jac/dkaa500.CrossRef

53.

VEKLURY® (remdesivir) Package Insert. https://www.vekluryhcp.com/. Accessed 17 Dec 2020.

54.

Cojutti PG, Londero A, Della Siega P, Givone F, Fabris M, Biasizzo J, et al. Comparative population pharmacokinetics of Darunavir in SARS-CoV-2 patients vs. HIV patients: the role of Interleukin-6. Clin Pharmacokinet. 2020;59(10):1251–60. https://doi.org/10.1007/s40262-020-00933-8.CrossRefPubMedPubMedCentral

55.

Le MP, Jaquet P, Patrier J, Wicky PH, Le Hingrat Q, Veyrier M, et al. Pharmacokinetics of lopinavir/ritonavir oral solution to treat COVID-19 in mechanically ventilated ICU patients. J Antimicrob Chemother. 2020;75(9):2657–60. https://doi.org/10.1093/jac/dkaa261.CrossRefPubMed

56.

Thakur A, Tan SPF, Chan JCY. Physiologically-based pharmacokinetic modeling to predict the clinical efficacy of the coadministration of lopinavir and ritonavir against SARS-CoV-2. Clin Pharmacol Ther. 2020;108(6):1176–84. https://doi.org/10.1002/cpt.2014.CrossRefPubMed

57.

Alvarez JC, Moine P, Davido B, Etting I, Annane D, Larabi IA, et al. Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients. Eur J Clin Pharmacol. 2020. https://doi.org/10.1007/s00228-020-03020-w.CrossRefPubMedPubMedCentral

58.

Marzolini C, Stader F, Stoeckle M, Franzeck F, Egli A, Bassetti S, et al. Effect of systemic inflammatory response to SARS-CoV-2 on lopinavir and hydroxychloroquine plasma concentrations. Antimicrob Agents Chemother. 2020. https://doi.org/10.1128/AAC.01177-20.CrossRefPubMedPubMedCentral

59.

Schoergenhofer C, Jilma B, Stimpfl T, Karolyi M, Zoufaly A. Pharmacokinetics of lopinavir and ritonavir in patients hospitalized with coronavirus disease 2019 (COVID-19). Ann Intern Med. 2020;173(8):670–2. https://doi.org/10.7326/M20-1550.CrossRefPubMed

60.

Meziyerh S, Zwart TC, van Etten RW, Janson JA, van Gelder T, Alwayn IPJ, et al. Severe COVID-19 in a renal transplant recipient: a focus on pharmacokinetics. Am J Transplant. 2020;20(7):1896–901. https://doi.org/10.1111/ajt.15943.CrossRefPubMed

61.

Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. COVID-19: abnormal liver function tests. J Hepatol. 2020;73(3):566–74. https://doi.org/10.1016/j.jhep.2020.04.006.CrossRefPubMedPubMedCentral

62.

Shokri Afra H, Amiri-Dashatan N, Ghorbani F, Maleki I, Rezaei-Tavirani M. Positive association between severity of COVID-19 infection and liver damage: a systematic review and meta-analysis. Gastroenterol Hepatol Bed Bench. 2020;13(4):292–304.PubMedPubMedCentral

63.

Chen M, Suzuki A, Borlak J, Andrade RJ, Lucena MI. Drug-induced liver injury: interactions between drug properties and host factors. J Hepatol. 2015;63(2):503–14. https://doi.org/10.1016/j.jhep.2015.04.016.CrossRefPubMed

64.

Christensen H, Hermann M. Immunological response as a source to variability in drug metabolism and transport. Front Pharmacol. 2012;3:8. https://doi.org/10.3389/fphar.2012.00008.CrossRefPubMedPubMedCentral

65.

Viani A, Rizzo G, Carrai M, Pacifici GM. Interindividual variability in the concentrations of albumin and alpha-1-acid glycoprotein in patients with renal or liver disease, newborns and healthy subjects: implications for binding of drugs. Int J Clin Pharmacol Ther Toxicol. 1992;30(4):128–33.PubMed

66.

World Health Organization (WHO). R&D Blueprint and COVID-19 2020. https://www.who.int/teams/blueprint/covid-19. Accessed 14 Oct 2020.

67.

Doggrell SA. Remdesivir, a remedy or a ripple in severe COVID-19? Expert Opin Investig Drugs. 2020. https://doi.org/10.1080/13543784.2020.1821645.CrossRefPubMedPubMedCentral

68.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–99. https://doi.org/10.1056/NEJMoa2001282.CrossRefPubMed

69.

U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine. 2020. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and. Accessed 14 Oct 2020.

70.

Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020;57:279–83. https://doi.org/10.1016/j.jcrc.2020.03.005.CrossRefPubMedPubMedCentral

71.

Nefic H. The genetic variation of CYP2D6 gene in the Bosnian population. Med Arch. 2018;72(6):396–400. https://doi.org/10.5455/medarh.2018.72.396-400.CrossRefPubMedPubMedCentral

72.

Group RC, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with Covid-19—preliminary report. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2021436.CrossRef

73.

Doi M, Kajikawa N, Aiba T. Effects of dexamethasone to reverse decreased hepatic midazolam metabolism in rats with acute renal failure. Xenobiotica. 2020;50(5):506–14. https://doi.org/10.1080/00498254.2019.1655680.CrossRefPubMed

74.

Deb S, Pandey M, Adomat H, Guns ES. Cytochrome P450 3A-mediated microsomal biotransformation of 1alpha,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism. Drug Metab Dispos. 2012;40(5):907–18. https://doi.org/10.1124/dmd.111.041681.CrossRefPubMed

75.

Kadmiel M, Cidlowski JA. Glucocorticoid receptor signaling in health and disease. Trends Pharmacol Sci. 2013;34(9):518–30. https://doi.org/10.1016/j.tips.2013.07.003.CrossRefPubMedPubMedCentral

76.

Meyer MR, Maurer HH. Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse. Pharmacogenomics. 2011;12(2):215–33. https://doi.org/10.2217/pgs.10.171.CrossRefPubMed

77.

Katoh M, Nakajima M, Yamazaki H, Yokoi T. Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4. Pharm Res. 2000;17(10):1189–97. https://doi.org/10.1023/a:1007568811691.CrossRefPubMed

78.

Sutton D, Butler AM, Nadin L, Murray M. Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. J Pharmacol Exp Ther. 1997;282(1):294–300.PubMed

79.

Tateishi T, Ohashi K, Fujimura A, Ebihara A. The influence of diltiazem versus cimetidine on propranolol metabolism. J Clin Pharmacol. 1992;32(12):1099–104.PubMed

80.

Zhang Y, Guo X, Lin ET, Benet LZ. Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor. Drug Metab Dispos. 1998;26(4):360–6.PubMed

81.

McCrea JB, Cribb A, Rushmore T, Osborne B, Gillen L, Lo MW, et al. Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174. Clin Pharmacol Ther. 1999;65(3):348–52. https://doi.org/10.1016/S0009-9236(99)70114-1.CrossRefPubMed

82.

Cook CS, Berry LM, Kim DH, Burton EG, Hribar JD, Zhang L. Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: differential metabolism by CYP3A4 and CYP3A5. Drug Metab Dispos. 2002;30(12):1344–51. https://doi.org/10.1124/dmd.30.12.1344.CrossRefPubMed

83.

Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther. 1996;60(1):54–61. https://doi.org/10.1016/S0009-9236(96)90167-8.CrossRefPubMed

84.

Suzuki K, Yanagawa T, Shibasaki T, Kaniwa N, Hasegawa R, Tohkin M. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diabetes Res Clin Pract. 2006;72(2):148–54. https://doi.org/10.1016/j.diabres.2005.09.019.CrossRefPubMed

85.

Yao TT, Qian JD, Zhu WY, Wang Y, Wang GQ. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option. J Med Virol. 2020;92(6):556–63. https://doi.org/10.1002/jmv.25729.CrossRefPubMedPubMedCentral

86.

U.S. National Library of Medicine. ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world. 2020. https://clinicaltrials.gov/. Accessed 14 Oct 2020.

87.

Mimura H, Kobayashi K, Xu L, Hashimoto M, Ejiri Y, Hosoda M, et al. Effects of cytokines on CYP3A4 expression and reversal of the effects by anti-cytokine agents in the three-dimensionally cultured human hepatoma cell line FLC-4. Drug Metab Pharmacokinet. 2015;30(1):105–10. https://doi.org/10.1016/j.dmpk.2014.09.004.CrossRefPubMed

88.

Chima M, Lebwohl M. TNF inhibitors for psoriasis. Semin Cutan Med Surg. 2018;37(3):134–42. https://doi.org/10.12788/j.sder.2018.039.CrossRefPubMed

89.

Zhang R, Wang X, Ni L, Di X, Ma B, Niu S, et al. COVID-19: melatonin as a potential adjuvant treatment. Life Sci. 2020;250:117583. https://doi.org/10.1016/j.lfs.2020.117583.CrossRefPubMedPubMedCentral

90.

Hoyer J, Schulte KL, Lenz T. Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure. Clin Pharmacokinet. 1993;24(3):230–54. https://doi.org/10.2165/00003088-199324030-00005.CrossRefPubMed

91.

Ellison DH. Clinical pharmacology in diuretic use. Clin J Am Soc Nephrol. 2019;14(8):1248–57. https://doi.org/10.2215/CJN.09630818.CrossRefPubMedPubMedCentral

92.

Lee JY, Vinayagamoorthy N, Han K, Kwok SK, Ju JH, Park KS, et al. Association of polymorphisms of cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2016;68(1):184–90. https://doi.org/10.1002/art.39402.CrossRefPubMed

93.

Matsuoka A, Hirota Y, Takeda A, Kishi M, Hashimoto N, Ohara T, et al. Relationship between glycated hemoglobin level and duration of hypoglycemia in type 2 diabetes patients treated with sulfonylureas: a multicenter cross-sectional study. J Diabetes Investig. 2020;11(2):417–25. https://doi.org/10.1111/jdi.13132.CrossRefPubMed

94.

Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne). 2019;10:155. https://doi.org/10.3389/fendo.2019.00155.CrossRef

95.

Lundgren M, Darnerud PO, Molin Y, Lilienthal H, Blomberg J, Ilback NG. Viral infection and PBDE exposure interact on CYP gene expression and enzyme activities in the mouse liver. Toxicology. 2007;242(1–3):100–8. https://doi.org/10.1016/j.tox.2007.09.014.CrossRefPubMed

96.

Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763. https://doi.org/10.1016/j.ebiom.2020.102763.CrossRefPubMedPubMedCentral

97.

Zhang Y, Zheng L, Liu L, Zhao M, Xiao J, Zhao Q. Liver impairment in COVID-19 patients: a retrospective analysis of 115 cases from a single centre in Wuhan city, China. Liver Int. 2020;40(9):2095–103. https://doi.org/10.1111/liv.14455.CrossRefPubMed

98.

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–9. https://doi.org/10.1172/JCI137244.CrossRefPubMedPubMedCentral

99.

Deng Y, Liu W, Liu K, Fang YY, Shang J, Zhou L, et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study. Chin Med J (Engl). 2020;133(11):1261–7. https://doi.org/10.1097/CM9.0000000000000824.CrossRef

100.

Wang D, Yin Y, Hu C, Liu X, Zhang X, Zhou S, et al. Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China. Crit Care. 2020;24(1):188. https://doi.org/10.1186/s13054-020-02895-6.CrossRefPubMedPubMedCentral

101.

Shi S, Qin M, Cai Y, Liu T, Shen B, Yang F, et al. Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019. Eur Heart J. 2020;41(22):2070–9. https://doi.org/10.1093/eurheartj/ehaa408.CrossRefPubMed

102.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–9. https://doi.org/10.1001/jama.2020.1585.CrossRefPubMedPubMedCentral

103.

Aggarwal S, Garcia-Telles N, Aggarwal G, Lavie C, Lippi G, Henry BM. Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): early report from the United States. Diagnosis (Berl). 2020;7(2):91–6. https://doi.org/10.1515/dx-2020-0046.CrossRef

104.

Zheng Y, Xu H, Yang M, Zeng Y, Chen H, Liu R, et al. Epidemiological characteristics and clinical features of 32 critical and 67 noncritical cases of COVID-19 in Chengdu. J Clin Virol. 2020;127:104366. https://doi.org/10.1016/j.jcv.2020.104366.CrossRefPubMedPubMedCentral

105.

Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J. 2020. https://doi.org/10.1183/13993003.00524-2020.CrossRefPubMedPubMedCentral

106.

Violi F, Cangemi R, Romiti GF, Ceccarelli G, Oliva A, Alessandri F, et al. Is albumin predictor of mortality in COVID-19? Antioxid Redox Signal. 2020. https://doi.org/10.1089/ars.2020.8142.CrossRefPubMed

107.

Bonetti G, Manelli F, Patroni A, Bettinardi A, Borrelli G, Fiordalisi G, et al. Laboratory predictors of death from coronavirus disease 2019 (COVID-19) in the area of Valcamonica, Italy. Clin Chem Lab Med. 2020;58(7):1100–5. https://doi.org/10.1515/cclm-2020-0459.CrossRefPubMed

108.

Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol. 2020;92(7):797–806. https://doi.org/10.1002/jmv.25783.CrossRefPubMed

109.

Chen X, Yan L, Fei Y, Zhang C. Laboratory abnormalities and risk factors associated with in-hospital death in patients with severe COVID-19. J Clin Lab Anal. 2020. https://doi.org/10.1002/jcla.23467.CrossRefPubMedPubMedCentral

110.

Xia P, Wen Y, Duan Y, Su H, Cao W, Xiao M, et al. Clinicopathological features and outcomes of acute kidney injury in critically Ill COVID-19 with prolonged disease course: a retrospective cohort. J Am Soc Nephrol. 2020;31(9):2205–21. https://doi.org/10.1681/ASN.2020040426.CrossRefPubMedPubMedCentral

111.

Zeng Z, Yu H, Chen H, Qi W, Chen L, Chen G, et al. Longitudinal changes of inflammatory parameters and their correlation with disease severity and outcomes in patients with COVID-19 from Wuhan, China. Crit Care. 2020;24(1):525. https://doi.org/10.1186/s13054-020-03255-0.CrossRefPubMedPubMedCentral

112.

Liu J, Dong YQ, Yin J, He G, Wu X, Li J, et al. Critically ill patients with COVID-19 with ECMO and artificial liver plasma exchange: a retrospective study. Medicine (Baltimore). 2020;99(26):e21012. https://doi.org/10.1097/MD.0000000000021012.CrossRef

113.

Dickmann LJ, Patel SK, Wienkers LC, Slatter JG. Effects of interleukin 1beta (IL-1beta) and IL-1beta/interleukin 6 (IL-6) combinations on drug metabolizing enzymes in human hepatocyte culture. Curr Drug Metab. 2012;13(7):930–7. https://doi.org/10.2174/138920012802138642.CrossRefPubMed

114.

Rubin K, Janefeldt A, Andersson L, Berke Z, Grime K, Andersson TB. HepaRG cells as human-relevant in vitro model to study the effects of inflammatory stimuli on cytochrome P450 isoenzymes. Drug Metab Dispos. 2015;43(1):119–25. https://doi.org/10.1124/dmd.114.059246.CrossRefPubMed

115.

Guillen MI, Donato MT, Jover R, Castell JV, Fabra R, Trullenque R, et al. Oncostatin M down-regulates basal and induced cytochromes P450 in human hepatocytes. J Pharmacol Exp Ther. 1998;285(1):127–34.PubMed

116.

Liptrott NJ, Penny M, Bray PG, Sathish J, Khoo SH, Back DJ, et al. The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC. Br J Pharmacol. 2009;156(3):497–508. https://doi.org/10.1111/j.1476-5381.2008.00050.x.CrossRefPubMedPubMedCentral

117.

Gregoire M, Le Turnier P, Gaborit BJ, Veyrac G, Lecomte R, Boutoille D, et al. Lopinavir pharmacokinetics in COVID-19 patients. J Antimicrob Chemother. 2020;75(9):2702–4. https://doi.org/10.1093/jac/dkaa195.CrossRefPubMed

118.

Baldelli S, Corbellino M, Clementi E, Cattaneo D, Gervasoni C. Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose? J Antimicrob Chemother. 2020;75(9):2704–6. https://doi.org/10.1093/jac/dkaa190.CrossRefPubMed

Title: Potential Effects of COVID-19 on Cytochrome P450-Mediated Drug Metabolism and Disposition in Infected Patients
Authors: Subrata Deb
Scott Arrighi
Publication date: 01-03-2021
Publisher: Springer International Publishing
Keywords: SARS-CoV-2
COVID-19
Cytokines
Published in: European Journal of Drug Metabolism and Pharmacokinetics / Issue 2/2021
Print ISSN: 0378-7966
Electronic ISSN: 2107-0180
DOI: https://doi.org/10.1007/s13318-020-00668-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Potential Effects of COVID-19 on Cytochrome P450-Mediated Drug Metabolism and Disposition in Infected Patients

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2021

Pharmacokinetics of Morphine and Morphine-6-Glucuronide During Postoperative Pain Therapy in Cardiac Surgery Patients

Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers

Prediction of Half-Life Extension of Peptides via Serum Albumin Binding: Current Challenges

Pharmacokinetic Modelling of Human Recombinant Protein, p75ECD-Fc: A Novel Therapeutic Approach for Treatment of Alzheimer’s Disease, in Serum and Tissue of Sprague Dawley Rats

Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms

Feasibility of Using Oral Fluid for Therapeutic Drug Monitoring of Antiepileptic Drugs